Apellis Medical Hub
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Retina Fellow Research Grant
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.
  • Menu Menu
  • Science
    • PNH
    • Geographic Atrophy
    • C3G and Primary IC-MPGN
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
    • Retina Fellow Research Grant
    • Exploratory Data Analysis
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
    • Community Letters
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.

Retina Fellow Research Grant

US Retina Fellow Research Grant

Apellis is committed to improving the lives of patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and supports medical and scientific research that demonstrates the highest standards of scientific integrity, inclusivity, and intellectual curiosity.

Apellis is supporting US retina fellows by offering a research grant of up to $50,000, awarded based on its scientific merit and impact on patients. Research applications should have the following scientific focus:

  • Imaging and diagnostic strategies for GA
  • Real-world insights on pegcetacoplan efficacy and safety
  • Pegcetacoplan in underrepresented patient phenotypes
  • Pegcetacoplan dosing strategies

Application Requirements

Applications must be submitted through the online submission portal linked below. The following information is required for the US Retina Fellow Grant application:

  • Proof of enrollment in a US based vitreoretinal/medical retina fellowship program
  • Supporting documentation (i.e., CV) for the applicant and the applicant’s director/mentor
  • Research Plan (see submission portal for more details)

Review Process

Applications to the US Retina Fellow Research Grant will be reviewed on a rolling basis up until the submission deadline. Following a selection of top applications by the US GA Medical Director Team, a steering committee of US Retina Specialists will review the finalists in a de-identified fashion based on the research merit criteria.

Timeline 

The submission portal will be open for applications up to August 20, 2025 at 11:59 ET. Following closure of the submission portal on August 20, applications will be reviewed as outlined above. The process is anticipated to take 3-4 weeks, at which point the applicant with the selected submission will be notified.

Apply now for the Retina Fellow Grant

Report an Adverse Event or Product complaint

Please call 833-866-3346

Ask a Medical Question

Please click here or call
833-866-3346 (833-TO-MEDINFO)

Connect with an MSL

Set up a meeting with your
Medical Science Liaison

Privacy PolicyTerms and Conditions

©2025 Apellis Pharmaceuticals, Inc. All rights reserved. 04/25 MED-US-CORP-22-00001 v11.0
Scroll to top
You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.

I agree
Landing

Landing

You are entering a website that is technical in nature and was created for scientific exchange with Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.
Are you a Healthcare Professional licensed to practice in the country or region selected above? If you are not a Healthcare Professional, you will be redirected to www.apellis.com(Required)
Enter
Enter
Enter
Enter
Enter
Enter